Health Rounds newsletter excerpt has been corrected to indicate in the headline and the first item of the story that Sanofi ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Roger Black required surgery after blaming his weariness on simply getting older and the Olympic silver medalist was given a ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

The American Heart Association is dedicated to raising awareness about heart valve disease through initiatives like Target: ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

Heart Valve Disease Awareness Day, observed annually on February 22, is dedicated to educating the public about the risks, ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...